A Randomized, Double-Blind, Placebo-Controlled Phase III Study of Oral SB1518 in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) and with Thrombocytopenia

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of Oral SB1518 in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) and with Thrombocytopenia

Discontinued
Phase of Trial: Phase III

Latest Information Update: 05 Mar 2013

At a glance

  • Drugs Pacritinib (Primary)
  • Indications Myelofibrosis; Polycythaemia vera; Thrombocytosis
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 05 Mar 2013 Status changed from planning to discontinued.
    • 01 Aug 2012 Planned initiation date changed to 1 Dec 2012.
    • 06 Oct 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top